Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 12,609 · FY2024 18,890 — 3-yr total 31,499
Pharmaceutical importer/distributor active in the Georgian market.
| Ratio | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Margins | ||||
| Gross Margin | 13.1% | 44.6% | 59.8% | 62.3% |
| EBITDA Margin | -2.3% | 35.1% | 47.4% | 51.7% |
| EBITDAR | -18 | 12,014 | 22,861 | 34,062 |
| EBITDAR Margin | -2.3% | 35.1% | 47.4% | 51.7% |
| EBIT Margin | -6.4% | 35.1% | 47.2% | 51.2% |
| Net Profit Margin | -9.8% | 35.3% | 46.2% | 50.4% |
| Operating Expense % of Sales | 15.4% | 9.5% | 12.4% | 10.7% |
| Returns | ||||
| Return on Assets (ROA) | -1.6% | 44.6% | 70.1% | 62.9% |
| Return on Equity (ROE) | N/A | 138.3% | 121.1% | 101.5% |
| ROIC [EBIT / Invested Capital] | -17.4% | 142.3% | 121.7% | 101.9% |
| Leverage & debt balances | ||||
| Debt-to-Assets | 8.5% | 1.5% | 1.3% | 0.8% |
| Debt-to-Equity | -5.43x | 0.05x | 0.02x | 0.01x |
| Debt-to-EBITDA | N/A | 0.03x | 0.02x | 0.01x |
| Equity-to-Assets | -1.6% | 32.3% | 57.9% | 62.0% |
| Net Debt | 358 | -294 | 321 | 394 |
| Cash & Equivalents | 45 | 713 | 99 | 29 |
| Total Debt | 403 | 419 | 420 | 424 |
| Liquidity & working capital | ||||
| Current Ratio | 0.94x | 1.43x | 2.22x | 2.50x |
| Quick Ratio | 0.15x | 1.04x | 1.96x | 2.08x |
| Cash Ratio | 0.01x | 0.04x | 0.01x | 0.00x |
| Total Current Assets | 4,509 | 26,097 | 29,667 | 50,145 |
| Total Current Liabilities | 4,813 | 18,285 | 13,379 | 20,066 |
| Inventory | 3,766 | 7,053 | 3,469 | 8,323 |
| Trade Receivables | 698 | 18,331 | 26,098 | 41,790 |
| Trade Payables | 4,409 | 17,848 | 12,959 | 19,642 |
| Net Working Capital | -304 | 7,812 | 16,288 | 30,079 |
| Net Working Capital % of Revenue | -39.2% | 22.8% | 33.8% | 45.6% |
| Trade Working Capital | 55 | 7,537 | 16,608 | 30,471 |
| Trade Working Capital % of Revenue | 7.1% | 22.0% | 34.4% | 46.2% |
| Change in Trade Working Capital | N/A | 7,481 | 9,071 | 13,863 |
| Turnover & efficiency | ||||
| Inventory Turnover | 0.18x | 2.68x | 5.58x | 2.99x |
| Days Inventory Outstanding (DIO) | 2040.1 | 136.0 | 65.4 | 122.2 |
| Receivables Turnover | 1.11x | 1.87x | 1.85x | 1.58x |
| Days Sales Outstanding (DSO) | 328.9 | 195.7 | 197.5 | 231.3 |
| Payables Turnover | 0.15x | 1.06x | 1.50x | 1.27x |
| Days Payable Outstanding (DPO) | 2388.3 | 344.1 | 244.1 | 288.5 |
| Cash Conversion Cycle | -19.4 days | -12.4 days | 18.7 days | 65.1 days |
| Asset Turnover | 0.16x | 1.27x | 1.52x | 1.25x |
| Cash flow & dividends | ||||
| Operating Cash Flow | -81 | 2,549 | 13,265 | 19,328 |
| Free Cash Flow (OCF − Capex proxy) | -342 | 1,842 | 12,002 | 18,473 |
| Cash Conversion (OCF / EBITDA) | N/A | 21.2% | 58.0% | 56.7% |
| Dividends Declared | N/A | 0 | 12,609 | 18,890 |
| Dividend Payout Ratio | N/A | 0.0% | 56.6% | 56.8% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →